Louisiana State Employees Retirement System Invests $578,000 in Enovis Corporation $ENOV

Louisiana State Employees Retirement System purchased a new stake in Enovis Corporation (NYSE:ENOV) in the first quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 25,400 shares of the company’s stock, valued at approximately $578,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ENOV. Arax Advisory Partners purchased a new stake in Enovis during the fourth quarter valued at approximately $29,000. EverSource Wealth Advisors LLC increased its position in shares of Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after purchasing an additional 707 shares during the last quarter. GAMMA Investing LLC raised its holdings in Enovis by 353.5% during the 4th quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock valued at $49,000 after buying an additional 1,446 shares during the period. Danske Bank A S purchased a new stake in Enovis during the 3rd quarter valued at $64,000. Finally, iSAM Funds UK Ltd bought a new stake in Enovis in the third quarter worth $80,000. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Insider Activity at Enovis

In other news, insider Oliver Engert purchased 1,200 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was acquired at an average cost of $21.62 per share, with a total value of $25,944.00. Following the completion of the transaction, the insider owned 51,840 shares in the company, valued at $1,120,780.80. This represents a 2.37% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders have bought 4,200 shares of company stock worth $92,084 over the last ninety days. Corporate insiders own 2.90% of the company’s stock.

Enovis Stock Performance

Shares of ENOV stock opened at $25.56 on Wednesday. The company has a quick ratio of 1.05, a current ratio of 2.04 and a debt-to-equity ratio of 0.87. The firm has a market cap of $1.47 billion, a price-to-earnings ratio of -1.29 and a beta of 1.39. The company’s 50 day moving average is $23.32 and its 200 day moving average is $23.83. Enovis Corporation has a 52-week low of $19.14 and a 52-week high of $36.82.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.89 EPS for the quarter, topping the consensus estimate of $0.82 by $0.07. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The firm had revenue of $589.15 million during the quarter, compared to analyst estimates of $572.02 million. During the same period in the previous year, the company posted $0.81 EPS. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, sell-side analysts anticipate that Enovis Corporation will post 3.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on ENOV shares. Wall Street Zen upgraded shares of Enovis from a “hold” rating to a “buy” rating in a research report on Monday. Zacks Research cut shares of Enovis from a “hold” rating to a “strong sell” rating in a research note on Tuesday, June 30th. Evercore set a $32.00 price target on shares of Enovis in a report on Monday. William Blair started coverage on shares of Enovis in a research note on Friday, April 17th. They issued an “outperform” rating for the company. Finally, BTIG Research restated a “buy” rating and set a $39.00 target price on shares of Enovis in a research report on Friday, May 22nd. Seven analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $43.83.

Enovis Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.